MOESM1 of Dapagliflozin improves treatment satisfaction in overweight patients with type 2 diabetes mellitus: a patient reported outcome study (PRO study)

Additional file 1. List of the 29 medical institutions participating in the study. The data on this file include the names of the 29 participating medical institutions in this multi-center study.